Laurus Labs Q1 FY27: ₹2,026 Cr revenue, 31.8% EBITDA

What stood out from the earnings call

Laurus Labs held its Q1 FY27 earnings conference call on July 24, 2026, with DAM Capital Advisors hosting the discussion. Management on the call included Founder and CEO Dr. Satyanarayana Chava, Executive Director and CFO V. V. Ravi Kumar, and business heads for CDMO, Generics and Commercial, along with investor relations.

Alongside the full earnings call, a compressed version of the roughly 61-minute concall was also referenced, shortened to about 27 minutes with analyst questions consolidated. The stated aim of that format was faster scanning while retaining all material guidance points, numbers, and management explanations from the original audio.

Q1 FY27 financial performance in numbers

The company reported revenue from operations of ₹2,026 crore in Q1 FY27, up 29% year-on-year. Gross margin was reported at 62.7%, an improvement of 3.3 percentage points year-on-year, reflecting a more favourable business mix.

EBITDA came in at ₹644 crore, translating into an EBITDA margin of 31.8%. Management commentary and call summaries highlighted that the EBITDA margin was up by about 7 percentage points, with one reference comparing it with 24.8% in the prior quarter.

Profit after tax (PAT) was ₹368 crore for the quarter. The company also reported return on capital employed (ROCE) of 19%, up from 17.7% in the prior year.

CDMO acceleration led the quarter

Management attributed the quarter’s momentum to strong demand for “multiple complex technology platforms” and integrated manufacturing capabilities, with a sharp acceleration in the CDMO business. CDMO revenue was reported at ₹835 crore, up 69% year-on-year.

In a separate call summary, CDMO revenue was also cited at ₹870 crore for Q1 FY27. The company’s disclosures in the provided material consistently pointed to CDMO as the key driver of the quarter’s step-up in growth and margins.

The company also said the CDMO business remains well diversified across customers, products, and therapeutic areas. Management referenced tangible progress in mid- and late-stage commercial projects with global innovators.

Commercial supplies and margin mix

On the call, management indicated that about 55% of small-molecule CDMO revenue came from commercial supplies, compared with 50% in the last financial year. The same section of the transcript also linked the mix shift to improving gross margin, with gross margin mentioned as improving from 61% to 63%.

This focus on later-stage and commercial work matters for investors because it typically influences utilisation levels, revenue visibility, and margins. In Laurus Labs’ case, the quarter’s reported gross margin and EBITDA margin expansion was repeatedly tied back to the segment mix.

Affordable Medicines and Bio division performance

Affordable Medicines revenue was reported at ₹1,156 crore, up 10% year-on-year. Management also described continued strength in the affordable medicines portfolio alongside the CDMO ramp-up.

The Bio division reported revenue of ₹35 crore, up 21% year-on-year. The call agenda also referenced Laurus Bio and “precision fermentation outlook”, indicating management time spent on longer-term platform build-outs, although the provided excerpt is limited to high-level items.

Capex, balance sheet, and leverage snapshot

Quarterly capex was reported at ₹394 crore. The material also stated that capex represented 19% of revenue during the quarter.

Net debt was reported at ₹2,656 crore, and the debt-to-EBITDA ratio was cited at 1.28. Management also raised FY27 capex guidance to ₹2,000 crore, with call summaries citing the earlier guidance as ₹1,500 crore.

One of the summaries also referenced a higher jump in capex guidance “from ₹1,000 crore to ₹2,000 crore for FY27”, but the more consistent reference in the provided notes was the move to ₹2,000 crore from ₹1,500 crore.

Regulatory and operating execution notes

The company said it passed 24 quality audits during the quarter without any critical findings. For a pharma manufacturer with multiple technology platforms and regulated market exposure, such disclosures are relevant because they support continuity of supplies and customer confidence.

The chapter list in the provided material also flagged discussions on operating cash flow, constant currency growth, customer advances, ARV revenue split, exchange gains, advanced biologics and new modalities, and the Karka JV. However, the excerpted text provided did not include detailed numeric disclosures for each of these items.

Market reaction: stock moved closer to 52-week high

The provided summary noted that Laurus Labs shares rose 2.1% to 1,601.2 after the results commentary, leaving it close to its 52-week high of 1,610. Another line noted a move from the previous close of 1,568.3.

This market move was reported alongside the narrative that Q1 FY27 was the company’s strongest quarter so far across major operating metrics, driven by CDMO execution and steady growth in the Affordable Medicines segment.

Key metrics table

Why this quarter mattered

The quarter combined two elements that markets tend to watch closely in pharma and CDMO-led stories: fast growth and a visible margin step-up. Laurus Labs reported a 29% revenue increase and a materially higher EBITDA margin, with management repeatedly linking the shift to CDMO momentum and higher commercial contribution.

The other key takeaway was the capex reset. Raising FY27 capex guidance to ₹2,000 crore signals that management sees demand-linked capacity needs, and it also frames investor expectations on cash flows, leverage, and commissioning timelines.

What to track next

Based on the call agenda and the metrics disclosed, investors will likely track whether the CDMO mix continues to skew toward commercial supplies and whether the improved margin profile sustains at higher volumes. Monitoring capex execution against the revised FY27 guidance will also remain central, alongside net debt movement and the debt-to-EBITDA ratio.

The company has directed readers to the complete earnings call transcript and audio recording for the full management commentary and Q&A detail beyond the excerpted items shared in the provided material.